Q2 EPS Estimate for Vanda Pharmaceuticals Reduced by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2025 earnings estimates for shares of Vanda Pharmaceuticals in a research note issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.35) per share for the quarter, down from their previous estimate of ($0.19). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals' Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.38) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.03 EPS.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They set a "hold" rating for the company.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA traded up $0.15 during midday trading on Friday, reaching $4.31. 547,638 shares of the stock traded hands, compared to its average volume of 722,826. Vanda Pharmaceuticals has a 12-month low of $3.81 and a 12-month high of $6.75. The business has a 50-day moving average of $4.42 and a two-hundred day moving average of $4.63. The stock has a market capitalization of $254.01 million, a PE ratio of -13.47 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The company had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million.

Insiders Place Their Bets

In related news, CEO Mihael Hristos Polymeropoulos purchased 20,000 shares of the firm's stock in a transaction on Friday, May 16th. The stock was acquired at an average price of $4.22 per share, with a total value of $84,400.00. Following the completion of the acquisition, the chief executive officer now owns 2,315,731 shares in the company, valued at approximately $9,772,384.82. This represents a 0.87% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders purchased 52,000 shares of company stock valued at $235,580. Insiders own 10.00% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantinno Capital Management LP purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $48,000. Linden Thomas Advisory Services LLC purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth $49,000. XTX Topco Ltd purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $69,000. Nations Financial Group Inc. IA ADV purchased a new position in shares of Vanda Pharmaceuticals during the first quarter worth $67,000. Finally, Zacks Investment Management purchased a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $74,000. Hedge funds and other institutional investors own 88.14% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.